Literature DB >> 14729225

Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors.

Manuella P Kaster1, Angelo Oscar Rosa, Matheus M Rosso, Eduardo C Goulart, Adair R S Santos, Ana Lúcia S Rodrigues.   

Abstract

This study investigated the effect of adenosine in the forced swimming test (FST) and the tail suspension test (TST) in mice, and the contribution of adenosine A1 and A2A receptors to adenosine's antidepressant-like effect. The immobility time in the FST was reduced by adenosine given either by i.p. (5-10 mg/kg) or i.c.v. (0.01-10 microg/site) route. Adenosine (1-10 mg/kg, i.p.) also produced an antidepressant-like effect in the TST. No treatment affected locomotion in an open-field. The anti-immobility effect of adenosine (10 mg/kg, i.p.) in the FST was prevented by i.p. pretreatment of mice with caffeine (3 mg/kg), DPCPX (2 mg/kg) and ZM241385 (1 mg/kg). CHA (0.05 mg/kg, i.p.) and DPMA (1-5 mg/kg, i.p.) also produced an antidepressant-like effect in the FST. This is the first report of an antidepressant-like effect of adenosine in mice, apparently mediated through an interaction with A1 and A2A receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14729225     DOI: 10.1016/j.neulet.2003.10.040

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  42 in total

Review 1.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

2.  A1 adenosine receptor-mediated GIRK channels contribute to the resting conductance of CA1 neurons in the dorsal hippocampus.

Authors:  Chung Sub Kim; Daniel Johnston
Journal:  J Neurophysiol       Date:  2015-02-04       Impact factor: 2.714

3.  Astrocyte-originated ATP protects Aβ(1-42)-induced impairment of synaptic plasticity.

Authors:  Eun Sun Jung; Kyongman An; Hyun Seok Hong; Joung-Hun Kim; Inhee Mook-Jung
Journal:  J Neurosci       Date:  2012-02-29       Impact factor: 6.167

Review 4.  Astrocytic adenosine: from synapses to psychiatric disorders.

Authors:  Dustin J Hines; Philip G Haydon
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-10-19       Impact factor: 6.237

Review 5.  Purinergic system in psychiatric diseases.

Authors:  A Cheffer; A R G Castillo; J Corrêa-Velloso; M C B Gonçalves; Y Naaldijk; I C Nascimento; G Burnstock; H Ulrich
Journal:  Mol Psychiatry       Date:  2017-09-26       Impact factor: 15.992

6.  Signaling pathways underlying the antidepressant-like effect of inosine in mice.

Authors:  Filipe Marques Gonçalves; Vivian Binder Neis; Débora Kurrle Rieger; Mark William Lopes; Isabella A Heinrich; Ana Paula Costa; Ana Lúcia S Rodrigues; Manuella P Kaster; Rodrigo Bainy Leal
Journal:  Purinergic Signal       Date:  2016-12-13       Impact factor: 3.765

7.  The antidepressant-like effect of inosine in the FST is associated with both adenosine A1 and A 2A receptors.

Authors:  Manuella P Kaster; Josiane Budni; Marta Gazal; Mauricio P Cunha; Adair R S Santos; Ana Lúcia S Rodrigues
Journal:  Purinergic Signal       Date:  2013-04-25       Impact factor: 3.765

8.  Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.

Authors:  Hai-Ying Shen; Jiang-Fan Chen
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

9.  Tuning and fine-tuning of synapses with adenosine.

Authors:  A M Sebastião; J A Ribeiro
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

10.  Extending the Specificity of DRL 72-s Behavior for Screening Antidepressant-Like Effects of Glutamatergic Clinically Validated Anxiolytic or Antidepressant Drugs in Rats.

Authors:  Gerard J Marek; Allyson A Salek
Journal:  J Pharmacol Exp Ther       Date:  2020-04-07       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.